Johns Hopkins Medicine has launched a groundbreaking clinical trial investigating the potential of tetracycline in addressing persistent symptoms following Lyme disease treatment, marking a significant step forward in the search for effective therapeutic options for post-Lyme complications.
Study Design and Objectives
The clinical trial focuses on evaluating three key aspects of tetracycline treatment: feasibility, tolerability, and its specific impact on fatigue - a common persistent symptom in post-Lyme patients. This targeted approach aims to provide valuable insights into managing one of the most challenging aspects of post-Lyme disease syndrome.
Patient Eligibility Criteria
The research team has established specific criteria for participation in the trial. Eligible candidates must:
- Be between 18 and 80 years of age
- Have a documented history of physician-diagnosed and treated Lyme disease within the past 10 years
- Experience ongoing symptoms that emerged within one year following initial Lyme disease treatment
Clinical Significance
This investigation holds particular importance in the field of Lyme disease research, as persistent symptoms following treatment represent a significant clinical challenge. While standard antibiotic protocols are effective for acute Lyme disease, a subset of patients continues to experience debilitating symptoms even after completing initial treatment.
Addressing an Unmet Medical Need
Post-treatment Lyme disease symptoms can significantly impact patients' quality of life, with fatigue being one of the most commonly reported issues. This trial represents an important step in addressing this unmet medical need, potentially offering new hope for patients who continue to struggle with persistent symptoms.
Interested individuals who meet the eligibility criteria are encouraged to contact the research team directly at 410-870-5963 or via email at lymeresearch@jhmi.edu for additional information about participation in this important clinical investigation.
